In the last trading session, 1.43 million Prelude Therapeutics Inc (NASDAQ:PRLD) shares changed hands as the company’s beta touched 1.40. With the company’s per share price at $1.24 changed hands at -$0.06 or -4.62% during last session, the market valuation stood at $99.91M. PRLD’s last price was a discount, traded about -448.39% off its 52-week high of $6.80. The share price had its 52-week low at $0.80, which suggests the last value was 35.48% up since then. When we look at Prelude Therapeutics Inc’s average trading volume, we note the 10-day average is 1.02 million shares, with the 3-month average coming to 425.48K.
Analysts gave the Prelude Therapeutics Inc (PRLD) stock a consensus recommendation rating of Sell, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 2 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended PRLD as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight.
Prelude Therapeutics Inc (NASDAQ:PRLD) trade information
Instantly PRLD was in red as seen at the end of in last trading. With action 38.44%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -70.96%, with the 5-day performance at 38.44% in the green. However, in the 30-day time frame, Prelude Therapeutics Inc (NASDAQ:PRLD) is 28.21% up. Looking at the short shares, we see there were 3.06 million shares sold at short interest cover period of 7.51 days.
The consensus price target for the stock as assigned by Wall Street analysts is 5, meaning bulls need an upside of 75.2% from its current market value. According to analyst projections, PRLD’s forecast low is 5 with 5 as the target high. To hit the forecast high, the stock’s price needs a -303.23% plunge from its current level, while the stock would need to soar -303.23% for it to hit the projected low.
Prelude Therapeutics Inc (PRLD) estimates and forecasts
Data shows that the Prelude Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -67.28% over the past 6 months, a 10.40% in annual growth rate that is considerably lower than the industry average of 16.40%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -43.14%. The 2024 estimates are for Prelude Therapeutics Inc earnings to increase by 12.13%, but the outlook for the next 5-year period is at 30.10% per year.
PRLD Dividends
Prelude Therapeutics Inc is expected to release its next quarterly earnings report in January.
Prelude Therapeutics Inc (NASDAQ:PRLD)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 9.36% of Prelude Therapeutics Inc shares while 84.98% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 93.76%. There are 84.98% institutions holding the Prelude Therapeutics Inc stock share, with ORBIMED ADVISORS LLC the top institutional holder. As of 2024-06-30, the company held 14.4043% of the shares, roughly 10.91 million PRLD shares worth $41.56 million.
BAKER BROS. ADVISORS LP holds the second largest percentage of outstanding shares, with 13.3673% or 10.12 million shares worth $38.57 million as of 2024-06-30.
